SLC5A2 and focal segmental glomerulosclerosis: In one pilot trial of SGLT2 inhibition in FSGS, proteinuria did not decrease after eight weeks of treatment with dapagliflozin which the authors theorized might relate to podocyte downregulation of SGLT2 mRNA which they observed in a archival renal biopsies of FSGS (58).